Negative vote for Avastin could have implications for cancer drug approvals
This article was originally published in Scrip
Executive Summary
The strongly negative vote by the FDA's oncologic drugs advisory committee (ODAC) - and an expected FDA decision now to take the extremely rare step of revoking the accelerated approval of Roche's Avastin (bevacizumab) for the treatment of first-line metastatic breast cancer - could have significant implications not only for Roche and the world's best-selling cancer drug but also for future approvals of oncology drugs. The committee members felt that the clinical benefit of Avastin in breast cancer had not been confirmed by the post-marketing studies in the disease.
You may also be interested in...
2011 Scrip 100: A new look at cancer chemoprevention
The development of drugs to prevent cancer has lagged far behind the development of drugs, such as the statins, to prevent cardiovascular disease. But consideration of new, "personalised" clinical trial designs and an improved understanding of the biology of precancers, as well as new agents which target their molecular abnormalities, may make the field a more promising investment, says Malini Guha.
Janssen-Cilag's Xeplion recommended for EU approval for schizophrenia
Janssen-Cilag's (Johnson & Johnson) injectable drug Xeplion (paliperidone palmitate) has been recommended for European approval by the CHMP for the treatment of schizophrenia.
Pfizer's Xiapex recommended for EU approval for Dupuytren's contracture
The CHMP has recommended for European approval Pfizer's Xiapex (collagenase clostridium histolyticum) for the treatment of Dupuytren’s contracture, a potentially debilitating hand condition.